| 000 | 01579 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250513072826.0 | ||
| 264 | 0 | _c19930819 | |
| 008 | 199308s 0 0 eng d | ||
| 022 | _a1018-8916 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGersuk, G M | |
| 245 | 0 | 0 |
_aQuantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity. _h[electronic resource] |
| 260 |
_bNatural immunity _c |
||
| 300 |
_a136-51 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aCell Separation |
| 650 | 0 | 4 |
_aCytotoxicity, Immunologic _xphysiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 |
_aInterferon Type I _xpharmacology |
| 650 | 0 | 4 |
_aInterleukin-2 _xpharmacology |
| 650 | 0 | 4 |
_aKiller Cells, Natural _xdrug effects |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyeloproliferative Disorders _ximmunology |
| 650 | 0 | 4 |
_aPlatelet-Derived Growth Factor _xphysiology |
| 650 | 0 | 4 |
_aPolycythemia Vera _ximmunology |
| 650 | 0 | 4 |
_aPrimary Myelofibrosis _ximmunology |
| 650 | 0 | 4 |
_aReceptors, IgG _xanalysis |
| 650 | 0 | 4 |
_aRecombinant Proteins _xpharmacology |
| 650 | 0 | 4 |
_aThrombocythemia, Essential _ximmunology |
| 700 | 1 | _aCarmel, R | |
| 700 | 1 | _aPattamakom, S | |
| 700 | 1 | _aChallita, P M | |
| 700 | 1 | _aRabinowitz, A P | |
| 700 | 1 | _aPattengale, P K | |
| 773 | 0 |
_tNatural immunity _gvol. 12 _gno. 3 _gp. 136-51 |
|
| 999 |
_c8329123 _d8329123 |
||